SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on
their Investment in BioMarin Pharmaceuticals, Inc. of Class Action Lawsuit and
Upcoming Deadline – BMRN
NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a
class action lawsuit has been filed against BioMarin Pharmaceuticals, Inc.
(“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers.
The class action, filed in United States District Court for the Northern
District of California, and docketed under 20-cv-06719, is on behalf of a
class consisting of all persons other than Defendants who purchased or
otherwise, acquired BioMarin securities between February 28, 2020 and August
18, 2020, both dates inclusive (the “Class Period”), seeking to recover
damages caused by Defendants’ violations of the federal securities laws and to
pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act
of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against
the Company and certain of its top officials.
If you are a shareholder who purchased BioMarin securities during the class
period, you have until November 24, 2020, to ask the Court to appoint you as
Lead Plaintiff for the class. A copy of the Complaint can be obtained at
www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at
firstname.lastname@example.org or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980.
Those who inquire by e-mail are encouraged to include their mailing address,
telephone number, and the number of shares purchased.
[Click here for information about joining the class action]
BioMarin is a biotechnology company that develops and commercializes therapies
for people with serious and life-threatening rare diseases and medical
conditions. The Company’s product candidates include, among others,
valoctocogene roxaparvovec, an investigational adeno-associated virus (“AAV”)
gene therapy, which is in Phase 3 clinical development for the treatment of
patients with severe hemophilia A.
… Read the rest